Alphamab Oncology (STU:3NK) Stock Based Compensation: €2.24 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:3NK Alphamab Oncology STU:3NK
55 GF Score
Price €0.89
GF Value €0.83
! 4 Warning Signs
View Full Analysis

What is Alphamab Oncology Stock Based Compensation?

Alphamab Oncology STU:3NK +2.89% 55 Stock Based Compensation is €2.24 Mil as of Dec. 2025. GuruFocus rates STU:3NK with a GF Score™ of 55/100 and a GF Value™ of €0.83. The stock has 4 warning signs investors should review.

Alphamab Oncology's Stock Based Compensation for the six months ended in Dec. 2025 was €2.19 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was €2.24 Mil.

Alphamab Oncology Stock Based Compensation Related Terms

Alphamab Oncology Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Alphamab Oncology's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alphamab Oncology Stock Based Compensation Chart

Alphamab Oncology Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only 1.14 1.80 1.98 0.33 2.24

Alphamab Oncology Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.46 0.14 0.19 0.05 2.19
STU:3NK
55GF Score
Alphamab Oncology STU:3NK
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alphamab Oncology Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €2.24 Mil.

What does a Stock Based Compensation of €2.24 Mil mean?
Alphamab Oncology (STU:3NK) has a Stock Based Compensation of €2.24 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Alphamab Oncology and its competitors.
Is Alphamab Oncology's Stock Based Compensation too high?
Alphamab Oncology's current Stock Based Compensation is €2.24 Mil. Overall, Alphamab Oncology has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Alphamab Oncology's Stock Based Compensation compare to VRTX and REGN?
Alphamab Oncology's Stock Based Compensation of €2.24 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Alphamab Oncology and its competitors. Alphamab Oncology's current Stock Based Compensation is €2.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alphamab Oncology stock overvalued right now?
Alphamab Oncology (STU:3NK) has a current Stock Based Compensation of €2.24 Mil. The stock's GF Value™ is €0.83, compared to a current price of €0.89 — trading 7.2% above its estimated fair value. The current Stock Based Compensation is €2.24 Mil. Alphamab Oncology's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Alphamab Oncology (STU:3NK), the current Stock Based Compensation is €2.24 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alphamab Oncology (STU:3NK) Overvalued in 2026?

Based on GuruFocus' analysis, Alphamab Oncology stock appears to be overvalued. The current stock price of €0.89 is trading 7.2% above its estimated GF Value™ of €0.83.

Key valuation signals for STU:3NK:

  • Stock Based Compensation: €2.24 Mil
  • GF Value™: €0.83 vs. price of €0.89 (7.2% above fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the STU:3NK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alphamab Oncology Business Description

Other Exchanges 09966:Hong Kong
Address No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215127
Alphamab Oncology is a biopharmaceutical company in China with a fully integrated proprietary technology platform in ADCs, bispecific antibodies, and multifunctional protein engineering. The Company is principally engaged in the research and development, manufacturing, and commercialisation of biologics of oncology. It delivers therapeutic biologics by applying its drug discovery and development capabilities. Its product portfolio includes Envafolimab (KN035), KN026, JSKN003, JSKN016, JSKN033, JSKN022, JSKN027, JSKN021, KN019, and KN046.
55GF Score

Get the complete analysis for STU:3NK

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.89
Price
€0.83
GF Value